HC Wainwright reissued their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $12.00 price objective on the stock.
Separately, Lake Street Capital reduced their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th.
Read Our Latest Stock Analysis on SRTS
Sensus Healthcare Price Performance
Shares of NASDAQ:SRTS traded up $0.02 during mid-day trading on Friday, reaching $4.59. 155,947 shares of the company traded hands, compared to its average volume of 308,354. The company's 50 day moving average price is $5.28 and its 200-day moving average price is $6.48. The firm has a market cap of $75.71 million, a PE ratio of 11.48 and a beta of 1.11. Sensus Healthcare has a 52 week low of $3.09 and a 52 week high of $9.33.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, research analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc purchased a new stake in Sensus Healthcare during the fourth quarter valued at $95,000. Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. XTX Topco Ltd raised its position in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock valued at $183,000 after buying an additional 13,619 shares in the last quarter. Virtu Financial LLC purchased a new position in Sensus Healthcare in the fourth quarter worth about $189,000. Finally, Integrated Quantitative Investments LLC bought a new stake in Sensus Healthcare during the fourth quarter worth approximately $251,000. 25.30% of the stock is owned by hedge funds and other institutional investors.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Stories
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
